1 nt the next generation of oxazolidinones and
lipoglycopeptides.
2 common to all glycopeptides (vancomycin) and
lipoglycopeptides.
3 o a lipopeptide tail, and in the case of the
lipoglycopeptides,
a deoxymannose moiety.
4 Oritavancin is a semisynthetic
lipoglycopeptide analogue of vancomycin that contains th
5 Dalbavancin, a
lipoglycopeptide antibiotic agent that is active against
6 following exposure of the macrophages to the
lipoglycopeptide antibiotic oritavancin.
7 Oritavancin is a
lipoglycopeptide antibiotic that has been shown to be ef
8 Telavancin is a bactericidal
lipoglycopeptide antibiotic that is active against a ran
9 Telavancin is a
lipoglycopeptide antibiotic with potent in vitro activit
10 Oritavancin is a
lipoglycopeptide antibiotic with rapid bactericidal acti
11 ubstantial intracellular accumulation with a
lipoglycopeptide antibiotic.
12 diversification of the glycolipid portion of
lipoglycopeptide antibiotics is simple to perform on a l
13 Dalbavancin is a
lipoglycopeptide antimicrobial agent with a potency sign
14 , the present discovery of a family of novel
lipoglycopeptides as potent inhibitors of bacterial SPas
15 The core structure of the arylomycins and
lipoglycopeptides consists of a biaryl-linked, N-methyla
16 Telavancin is a semisynthetic
lipoglycopeptide derivative of vancomycin.
17 on of a family of structurally related novel
lipoglycopeptides from a Streptomyces sp. as inhibitors
18 and became the first marketed semisynthetic
lipoglycopeptide in 2009.
19 Recently, the arylomycins and related
lipoglycopeptide natural products were isolated and show
20 s, including MS and NMR, revealed that these
lipoglycopeptides share a common 14-membered cyclic pept
21 In contrast to prior work with
lipoglycopeptides,
this study reveals the glucose C3' or
22 Oritavancin is a
lipoglycopeptide with bactericidal activity against gram